A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases

Inclusion criteria

• ✓. Female or male participants between the ages of 18 and 55 years inclusive (ages 18 and 45 years for Part C).
• ✓. BMI of 18 to 32 kg/m\^2; and a total body weight \> 50 kg (110 lbs).
• ✓. Evidence of a personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study.
• ✓. Participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
• ✓. Nonsterile male participants must be willing to use a highly effective method of birth control and refrain from sperm donation for the duration of the study and for 90 days after the last dose of study drug.
• ✓. Female participants of childbearing potential can only join Part F and must be willing to use a highly effective method of birth control and refrain from egg donation for the duration of the study and for 90 days after the last dose of study drug. They must also have a negative urine pregnancy test at baseline before first dose of study drug.
• ✓. Female or male participants between the ages of 18 to 75 years of age.
• ✓. Female participants of childbearing potential must be willing to use a highly effective method of birth control and refrain from egg donation for the duration of the study and for 90 days after the last dose of study drug. They must also have a negative urine pregnancy test at baseline before first dose of study drug.